Commitments and Contingencies (Details) - USD ($)	1 Months Ended			6 Months Ended
	Aug. 31, 2020	Jul. 31, 2017	Aug. 31, 2015	Jun. 30, 2020
License, Manufacture and Supply Agreement [Member]
Commitments and Contingencies [Line Items]
Royalty obligation description				Under the terms of the agreement, the Company will be required to pay a low single-digit percentage royalty on net sales of any products developed and commercialized under the agreement.
Asset Purchase Agreement [Member] | 1st Order Pharmaceuticals, Inc. [Member]
Commitments and Contingencies [Line Items]
Accrued milestone payment				$ 300,000
Royalty obligation	$ 0
Asset Purchase Agreement [Member] | 1st Order Pharmaceuticals, Inc. [Member] | Clinical Development Milestones [Member]
Commitments and Contingencies [Line Items]
Future potential payments	1,200,000
Asset Purchase Agreement [Member] | 1st Order Pharmaceuticals, Inc. [Member] | Regulatory Milestone [Member] | Maximum [Member]
Commitments and Contingencies [Line Items]
Future potential payments	6,000,000
Asset Purchase Agreement [Member] | 1st Order Pharmaceuticals, Inc. [Member] | Other Milestones [Member]
Commitments and Contingencies [Line Items]
Future potential payments	$ 500,000
License Agreement [Member]
Commitments and Contingencies [Line Items]
Royalty obligation description		low-to-mid single-digit percentage royalty on net sales of any products developed and commercialized under the agreement
License Agreement [Member] | Clinical Development Milestones [Member]
Commitments and Contingencies [Line Items]
Future potential payments		$ 2,000,000
License Agreement [Member] | Regulatory Milestone [Member] | Maximum [Member]
Commitments and Contingencies [Line Items]
Future potential payments		$ 7,000,000
Medpace Clinical Development Service Agreement [Member]
Commitments and Contingencies [Line Items]
Service agreement, term			5 years
Committed service obligation			$ 7,000,000	3,841,000
Contractual obligation paid				$ 3,159,000